



ASX ANNOUNCEMENT

8 July 2026

Results of Oversubscribed Share Purchase Plan

Vitrafy Life Sciences Limited (ASX: VFY) (“**Vitrafy**” or “**Company**”) is pleased to advise the results of its share purchase plan (“**SPP**”), which was announced on Friday, 12 June 2026. The SPP was open to eligible shareholders registered on the record date being 7:00pm AEST on Thursday, 11 June 2026 (“**Eligible Shareholders**”).

The SPP was offered at A\$2.60 per new fully paid ordinary share (“**New Share**” or “**SPP Shares**”) in the Company, being the same price as the institutional placement announced to the ASX on Friday, 12 June 2026 (“**Placement**”).

The SPP closed on Friday, 3 July 2026 and received strong support from Eligible Shareholders, with valid applications totalling approximately A\$9.4 million, exceeding the A\$2 million cap on the offer.

As disclosed in the SPP Booklet, the Board retained discretion regarding the allocation of SPP Shares in the event that applications exceeded the amount sought to be raised under the SPP. After considering the level of demand, the Board has exercised that discretion and determined to scale back all valid applications on a pro-rata basis to limit dilution and provide an equitable allocation of New Shares to participating shareholders.

Under the scale back methodology, each Eligible Shareholder will be allocated a proportion of the SPP Shares applied for equal to A\$2 million divided by the total value of all valid applications received under the SPP, with the resulting number of SPP Shares rounded to the nearest whole share. Any application monies received in excess of the value of SPP Shares allocated will be refunded in accordance with the terms of the SPP Booklet, without interest.

Following completion of the scale back, a total of 769,142 New Shares will be issued on Thursday, 9 July 2026, and will commence trading on Friday, 10 July 2026. Holding statements and any applicable refund payments will be dispatched to shareholders on or around Friday, 10 July 2026.

Funds raised in the SPP, together with the A\$30 million proceeds of the Placement, will be used towards the following:

- Funding the manufacturing of Guardion devices to meet anticipated demand;
- Accelerating the expansion of Vitrafy’s US sales and operations;
- Supporting general working capital; and
- Payment of the costs of the Placement and SPP.

ENDS



This announcement is authorised by the Board of Vitrafy Life Sciences Limited.

For further information contact:

Tim Sharpe
Vice President of Strategy & Corporate Development
investors@vitrafy.com

About Vitrafy

Vitrafy has developed a proprietary cryopreservation ecosystem including the Guardian cryopreservation freezing unit, and Lifechain™, a cloud-based software platform, to offer a complete cryopreservation solution. The Vitrafy ecosystem delivers a new standard of cryopreservation of biomaterial quality, empowering industries to retain the integrity of sensitive biological samples throughout the collection, storage and delivery process. Vitrafy's innovative approach combines cutting-edge technology and seamless software integration to optimise cryopreservation, ensuring reliability and efficiency in maintaining valuable biological assets.

Vitrafy is headquartered in Melbourne, Australia and is listed on the Australian Securities Exchange (ASX: VFY).

For more information visit vitrafy.com.

For personal use only